CMPS

8.0257.23%
DK

Daphne Karydas

Independent Director

Ms. Daphne Karydas, MBA, was President, Secretary & CFO of Flare Therapeutics Inc. from 2026 until September 2026. Ms. Karydas, was President, Treasurer, Secretary & CFO of Flare Therapeutics Inc. from 2023 to 2026. Ms. Karydas serves as an Independent Director of COMPASS Pathways plc since September 18, 2023. She is Independent Director of Mineralys Therapeutics, Inc. since September 13, 2023. She serves as President and Chief Financial Officer of Flare Therapeutics Inc. since 2023. Previously, she served as Chief Operating Officer at Flare Therapeutics, Inc. since October 2021. She serves as Treasurer and Secretary of Flare Therapeutics Inc. She joined Flare Therapeutics Inc. in October 2021. Ms. Karydas serves as Member of Advisory Board at Reviva Pharmaceuticals Holdings, Inc. She served as an Independent Director at LogicBio Therapeutics Inc. since December 10, 2020 until November 16, 2022. Ms. Karydas served as an Independent Director of Elicio Therapeutics Inc. since 2020 until June 1, 2023. She is an Independent Director of Eucrates Biomedical Acquisition Corp. She served as Chief Financial Officer at Syndax Pharmaceuticals, Inc. since July 13, 2020 until October 22, 2021 and served as its Treasurer until October 22, 2021. Ms. Karydas had been Senior Vice President of Corporate Financial Planning & Analysis and Strategy at Allergan plc since December 10, 2018 until May 8, 2020, where she oversaw financial and business strategy through the company's acquisition by Abbvie in May 2020. Prior to joining Allergan, Ms. Karydas spent over years in asset management and investment banking focused on the bio-pharmaceutical sector. She served as Senior Vice President of Global Investor Relations & Strategy at Allergan plc from April 17, 2017 to December 10, 2018. Ms. Karydas served as Vice President, Research Analyst and Portfolio Manager at The Boston Company Asset Management, LLC. She also previously held healthcare Analyst roles with JPMorgan Asset Management. Ms. Karydas was a Member of the core research team covering the health care sector has been employed since January 2006. Ms. Karydas was a Portfolio Manager at The Dreyfus Corporation and BNY Mellon Funds Trust - BNY Mellon Large Cap Market Opportunities Fund. She joined Dreyfus Funds in January 2006. Prior thereto, she served as Vice President of Goldman Sachs Asset Management, LLC from January 2004 to January 2006 and a Member of Goldman Sachs' healthcare investment banking team. She served as Executive Director and Senior Healthcare Analyst at J. P. Morgan Asset Management from January 2015 to April 2017. Ms. Karydas has industry experience as a leading institutional Investor and Financial Analyst in the biopharmaceutical sector, most recently at J. P. Morgan Asset Management. Earlier in her career, she was a Project Chemical Engineer at Merck & Co. Ms. Karydas holds a B. A. and M. S. in chemical engineering from the Massachusetts Institute of Technology and an M. B.A. from Harvard Business School.

Positions